Department of Cell Biology and Molecular Medicine, Cardiovascular Research Institute, Rutgers New Jersey Medical School, Newark, NJ, USA.
Center for Advanced Proteomics Research, Department of Biochemistry & Molecular Biology, Rutgers New Jersey Medical School, Newark, NJ, USA.
Cell Metab. 2019 May 7;29(5):1119-1134.e12. doi: 10.1016/j.cmet.2019.01.005. Epub 2019 Feb 7.
Obesity induces lipotoxic cardiomyopathy, a condition in which lipid accumulation in cardiomyocytes causes cardiac dysfunction. Here, we show that glycogen synthase kinase-3α (GSK-3α) mediates lipid accumulation in the heart. Fatty acids (FAs) upregulate GSK-3α, which phosphorylates PPARα at Ser280 in the ligand-binding domain (LBD). This modification ligand independently enhances transcription of a subset of PPARα targets, selectively stimulating FA uptake and storage, but not oxidation, thereby promoting lipid accumulation. Constitutively active GSK-3α, but not GSK-3β, was sufficient to drive PPARα signaling, while cardiac-specific knockdown of GSK-3α, but not GSK-3β, or replacement of PPARα Ser280 with Ala conferred resistance to lipotoxicity in the heart. Fibrates, PPARα ligands, inhibited phosphorylation of PPARα at Ser280 by inhibiting the interaction of GSK-3α with the LBD of PPARα, thereby reversing lipotoxic cardiomyopathy. These results suggest that GSK-3α promotes lipid anabolism through PPARα-Ser280 phosphorylation, which underlies the development of lipotoxic cardiomyopathy in the context of obesity.
肥胖会导致脂肪毒性心肌病,即脂肪在心肌细胞中的积累导致心脏功能障碍。在这里,我们发现糖原合酶激酶-3α(GSK-3α)介导了心脏中的脂质积累。脂肪酸(FAs)上调 GSK-3α,后者在配体结合域(LBD)中将 PPARα 磷酸化 Ser280。这种修饰配体独立地增强了一组 PPARα 靶基因的转录,选择性地刺激 FA 的摄取和储存,但不刺激氧化,从而促进脂质积累。组成性激活的 GSK-3α,但不是 GSK-3β,足以驱动 PPARα 信号通路,而心脏特异性敲低 GSK-3α,但不是 GSK-3β,或用 Ala 取代 PPARα Ser280,可使心脏对脂肪毒性产生抗性。贝特类药物,即 PPARα 配体,通过抑制 GSK-3α 与 PPARα 的 LBD 的相互作用,抑制了 PPARα Ser280 的磷酸化,从而逆转了脂肪毒性心肌病。这些结果表明,GSK-3α 通过 PPARα-Ser280 磷酸化促进脂肪生成,这是肥胖导致脂肪毒性心肌病的基础。